DUBLIN, IRELAND--(Marketwired - Nov 13, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 12/553,107 (U.S. publication number 2010-0062064), entitled "Method for Delivering A Pharmaceutical Composition to Patient in Need Thereof" that covers the U.S. approved medicine VIMOVO® (naproxen/esomeprazole) delayed release tablets. This Notice of Allowance...
↧